spotlight migrain asthma heart-failur
investig sever opportun across migrain asthma
cardiovascular landscap along key upcom catalyst cgrp market
model forecast peak sale aimovig vs consensu
conserv base declin market share ajovi teva emgal
volum net price growth patient-bas tezepelumab forecast
peak risk-adjust sale anticip pivot direct trial
adult uncontrolled/sever asthma expect readout patient-
base omecamtiv-mecarbil forecast peak risk-adjust sale
anticip galactic-hf cv-outcom studi data view current
share price attract entri point adjust model new pt
aimovig sale grew y/i primarili driven volum growth
net price growth declin guid slightli lower net price
expect drive volum growth cite market share
aimovig estim us patient elig cgrp therapi
estim net sale consensu
cgrp market model forecast peak sale aimovig
vs consensu conserv base declin market share
volum net price growth driven
improv forecast cgrp-class
penetr rate approach leav room new migrain
vs consensu base increas market penetr
price compar dupix anticip on-going pivot
direct trial adult uncontrolled/severe-asthma read-out
view tezepelumab potenti superior dupix base consist
sale omecamtiv-mecarbil cardiac myosin activ
hfref improv outcom select increas cardiac contractil
galactic-hf cv-outcom studi primari endpoint time cv-death
first hf-event studi power assess final hazard ratio
cv death anticip readout exhibit
view current share price attract entri point vs
nbi ytd especi ahead key upcom catalyst
believ unlock valu updat sale ep estim drive
new pt prior exhibit
year price histori
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next year margin expand manag
track record financi disciplin top line believ
posit maintain long-term revenu stabil
matur product declin new product continu grow
pipelin deliv steadi flow new product
offer dividend yield believ provid valuat
updat data kra inhibitor major
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top-lin essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit cgrp market model forecast aimovig peak sale vs consensu
base declin market share ajovi teva emgal robust
volum net price growth volum growth function growth total cgrp-treat patient
estim base total cgrp-elig patient total cgrp-class penetr rate
appli estim market share forecast annual count product
exhibit aimovig highest net price per vs ajovi emgal
forecast aimovig annual net price improv gradual declin gtn-adjust
exhibit oppenheim vs consensu estim aimovig annual sale
exhibit oppenheim vs consensu estim tezepelumab annual sale
exhibit view tezepelumab potenti superior dupix base consist aer
lower vs placebo across eosinophilic-level patient subtyp note dupix approv
asthma base primari endpoint on-going pivot direct trial tezepelumab
also test primari endpoint believ result de-risk expect readout
populationeosinophil cellsper cubic mleosinophil cellsper cubic mleosinophil cellsper cubic mleosinophil cellsper cubic mlaer week tezepelumabamg mg everi weeksamg mg everi weeksamg mg everi weeksplacebo everi populationeosinophil cell permicrolitereosinophil cellsper microlitereosinophil cell permicolitera week dupilumabdupilumab mg everi weeksplacebo ml everi weeksdupilumab mg everi weeksplacebo ml everi week amgen inc
exhibit omecamtiv mecarbil novel select cardiac myosin activ previous show
abil improv cardiac function decreas ventricular volum heart rate n-termin
prob-typ natriuret peptid patient chronic hf moa stabil pre-powerstrok state
myosin enabl myosin head undergo powerstrok systol omecamtiv
mecarbil develop address hypothesi direct activ human sarcomer
could augment cardiac perform without advers effect convent inotrop agent
exhibit galactic-hf cv-outcom studi hfref patient test hypothesi
omecamtiv-mecarbil safe improv symptom clinic outcom select increas
cardiac contractil primari endpoint time cv-death first hf-event studi power
assess final hazard-ratio cv-death anticip readout
exhibit dcf valuat support
amgndiscount analysi except per-shar data revenu incom chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate inc
net incom equiti invest bgne
stock price compani mention report
compani lly-nys cover
